After successful licensing of LT1001 to Syntano Technology Venture, and approval for over-the-counter (OTC) listing (TPEx:6535) by the board of Taipei Exchange (TPEx), Lumosa was awarded the 2016 Biotech Potential Benchmark from the Bioindustry Association and Bronze Medal in the innovation category of 2016 Taipei Biotechnology Award from Taipei City Government. Dr. Wendy Huang, CEO of Lumosa Therapeutics, was also invited to give speeches at several conferences and seminars during the 2016 BioTaiwan event.